April 02, 2026. 35 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Alabama’s medical cannabis program is preparing for retail sales to begin in Spring 2026, establishing a new treatment access point for clinicians to recommend cannabis to eligible patients.
Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
Cannabis cannabinoids CBD and CBG show potential therapeutic effects against fatty liver disease in research, offering clinicians evidence-based information for patient consultations regarding hepatic health.
Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
This article covers regulatory enforcement actions against cannabis beverage companies and highlights the FDA’s oversight challenges in an emerging billion-dollar market segment.
Read more →New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
A new cannabis policy group aims to base recommendations on scientific evidence and patient feedback, helping clinicians access evidence-based guidance for clinical practice.
Read more →New Top Cannabis Regulator Sets Priorities In First Board Meeting
A newly appointed cannabis regulator outlined initial priorities in their first board meeting, establishing early policy direction that will affect clinical practice standards and patient care guidelines.
Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil’s evolving cannabis regulations present new clinical practice frameworks and legal pathways for clinicians treating patients in Latin America’s largest market.
Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Two Cincinnati breweries are challenging Ohio’s prohibition on THC-infused beverages through legal action, affecting cannabis product regulation and availability in the state.
Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Ohio law restricts THC-infused beverage distribution in retail settings, affecting clinician recommendations for edible cannabis product availability and patient access to alternative consumption methods.
Read more →Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
Oregon lawmakers rejected legislation that would have limited THC concentrations in cannabis edibles, affecting clinicians’ ability to manage patient dosing and safety protocols.
Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
This article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal routes, relevant for clinicians seeking alternative administration pathways to maximize bioavailability and patient outcomes.
Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
CBD-dominant cannabis products demonstrate clinically significant anxiety reduction, providing evidence-based alternative treatment options for patients seeking non-intoxicating therapeutic interventions.
Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
A clinical trial demonstrated that cannabis extracts effectively reduce myofascial pain, providing evidence-based data for clinicians prescribing cannabis for musculoskeletal pain conditions.
Read more →The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
This legal update covers regulatory developments and compliance issues relevant to cannabis practice during March 2026, helping clinicians stay informed about evolving laws affecting patient care and business operations.
Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Marijuana gummies sold in Ohio were recalled, requiring clinicians to monitor patients for potential adverse effects and verify product safety status with dispensaries.
Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
A new organization has formed in advance of Medicare-funded cannabidiol clinical pilot programs, which could establish clinical evidence and reimbursement pathways for cannabis-based treatments in geriatric care.
Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
This article covers legal prohibition statuses affecting marijuana, which matters to clinicians because legal classifications determine prescribing authority, patient access, and liability in clinical practice.
Read more →Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
A Louisiana legislator introduced legislation to establish a legal, regulated recreational cannabis market through licensed dispensaries, expanding access beyond the existing medical program.
Read more →Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
A Georgia mother’s homemade medical cannabis formulation is now commercially available at dispensaries, potentially expanding standardized product options for patients and clinicians.
Read more →Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
Virginia’s adult-use cannabis sales legislation passed both legislative chambers and requires conference committee reconciliation, establishing regulatory framework for legal retail cannabis access.
Read more →Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
A Tennessee study examines medical marijuana’s therapeutic benefits and risks, relevant to clinicians as the state’s regulatory status remains undefined.
Read more →2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
The 2026 Utah legislature addresses cannabis, psychedelics, and kratom policy, relevant to clinicians as these substances have potential therapeutic applications and regulatory implications for clinical practice.
Read more →Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
Georgia legislation would restrict law enforcement’s ability to establish probable cause based solely on marijuana/cannabis/hemp odor, directly affecting cannabis clinicians’ patients’ legal protections.
Read more →Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
This article projects the prescription CBD market will reach $190.9 billion by 2032 with 23.48% annual growth, indicating expanding clinical demand and potential therapeutic applications for cannabidiol-based treatments.
Read more →1. Paste the article text 2. Share the specific news topic/headline 3. Provide the article’s main points
Read more →InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
InMed Pharmaceuticals discontinued its non-therapeutic cannabis program at subsidiary BayMedica, refocusing resources on pharmaceutical development—relevant to clinicians tracking cannabinoid therapeutic commercialization.
Read more →Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
Pediatricians address cannabis use disorder in children and adolescents, highlighting accessibility concerns—relevant for clinicians treating youth populations and understanding developmental risk factors.
Read more →West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
West Virginia legislature approved allocation of medical marijuana tax revenue, impacting funding for cannabis clinical programs and patient access infrastructure in the state.
Read more →The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
This article examines roadside THC detection methods and Saskatchewan Government Insurance’s strict impaired driving policy, relevant for clinicians assessing patient impairment and legal compliance.
Read more →‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
Tennessee legislation proposes legalizing cannabis and directing tax revenue to infrastructure repair, directly affecting clinicians’ ability to recommend cannabis as a legal therapeutic option.
Read more →One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword
A major Colorado dispensary chain was acquired, affecting cannabis product distribution, accessibility, and market consolidation relevant to clinicians recommending cannabis to patients.
Read more →Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN
This article examines how cannabis legalization correlates with increased marijuana use among US adults from historically marginalized populations, informing clinicians about changing epidemiology and patient demographics.
Read more →Scientists are raising new concerns about marijuana use in teens – KPBS
Adolescent cannabis use correlates with increased psychiatric risks including psychosis, depression, and anxiety; clinicians should understand developmental brain vulnerability during teen years.
Read more →Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure
This research examines whether placental biomarkers could identify schizophrenia risk from prenatal THC exposure, informing clinical counseling about reproductive safety and developmental outcomes.
Read more →Digest-Level Clinical Commentary
The fragmentation evident across these items, from regulatory inconsistency on THC beverages to emerging clinical evidence supporting cannabinoid formulations for specific conditions like anxiety and myofascial pain, suggests that cannabis medicine practice is entering a critical phase where clinical judgment increasingly diverges from state and federal policy frameworks. As a physician, I’m observing that patients and practitioners now have access to preliminary data supporting targeted cannabinoid applications, yet we simultaneously face product safety concerns, interstate regulatory chaos, and the absence of FDA-standard dosing guidelines that would normally accompany therapeutic agents. This disconnect between growing clinical evidence and inadequate regulatory infrastructure means responsible prescribing requires heightened vigilance around formulation quality, patient education, and documentation while advocating simultaneously for the research infrastructure that cannabis medicine still desperately lacks.
These digest items reflect a maturing cannabis market increasingly focused on product formulation, regulatory standardization, and clinical evidence generation. Key themes include the emergence of cannabinoid-based therapeutics for specific conditions like anxiety and myofascial pain, parallel regulatory efforts to establish safety standards around potency and delivery methods, and ongoing tension between commercial interests and public health oversight. The clinical field appears to be transitioning from anecdotal use toward structured research protocols and evidence-based applications, though regulatory fragmentation across jurisdictions remains a significant challenge to standardized clinical practice.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it: